convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting

[1]  L. Weinberger,et al.  Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform , 2019, Cell.

[2]  D. Powell,et al.  The Emergence of Universal Immune Receptor T Cell Therapy for Cancer , 2019, Front. Oncol..

[3]  M. Brenner,et al.  Chimeric Antigen Receptors for T-Cell Malignancies , 2019, Front. Oncol..

[4]  Elvira Khialeeva,et al.  Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory , 2018, Proceedings of the National Academy of Sciences.

[5]  J. Kench,et al.  Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma , 2018, Gut.

[6]  Michel Sadelain,et al.  Chimeric Antigen Receptor Therapy. , 2018, The New England journal of medicine.

[7]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[8]  F. Locke,et al.  CAR T cell therapy for B-cell lymphomas. , 2018, Best practice & research. Clinical haematology.

[9]  J. Trapani,et al.  Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity , 2018, Proceedings of the National Academy of Sciences.

[10]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[11]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  P. Moss,et al.  A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding , 2017, Science Signaling.

[13]  C. Turtle,et al.  Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies , 2017, Drugs.

[14]  R. Brentjens,et al.  IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ Tumor Cells without Need for Prior Conditioning , 2016 .

[15]  L. Hurton,et al.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.

[16]  D. Busch,et al.  Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. , 2016, The Journal of clinical investigation.

[17]  D. Fremont,et al.  Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy , 2016, Nature Communications.

[18]  L. Cooper,et al.  Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[20]  Russell M. Gordley,et al.  Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors , 2016, Cell.

[21]  David Allman,et al.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.

[22]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[23]  T. Marafioti,et al.  A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. , 2014, Blood.

[24]  Michel Sadelain,et al.  PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses , 2013, Science Translational Medicine.

[25]  Raphael Sandaltzopoulos,et al.  Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo , 2013, Cancer Immunology Research.

[26]  Michel Sadelain,et al.  Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells , 2012, Nature Biotechnology.

[27]  H. Reyburn,et al.  Human NKG2D-ligands: cell biology strategies to ensure immune recognition , 2012, Front. Immun..

[28]  V. Pande,et al.  Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15 , 2012, Nature Immunology.

[29]  R. Fuller,et al.  Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. , 2011, Cold Spring Harbor protocols.

[30]  S. Riddell,et al.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.

[31]  Andrew B. Caldwell,et al.  Systematic mutation and thermodynamic analysis of central tyrosine pairs in polyspecific NKG2D receptor interactions. , 2011, Molecular immunology.

[32]  M. Wittekind,et al.  Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.

[33]  G. A. Lazar,et al.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions , 2010, mAbs.

[34]  T. Stehle,et al.  Structure of the HCMV UL16-MICB Complex Elucidates Select Binding of a Viral Immunoevasin to Diverse NKG2D Ligands , 2010, PLoS pathogens.

[35]  T. Spies.  Regulation of NKG2D ligands: a purposeful but delicate affair , 2008, Nature Immunology.

[36]  Raffi Tonikian,et al.  Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries , 2007, Nature Protocols.

[37]  Yannick Jacques,et al.  Identification of an Interleukin-15α Receptor-binding Site on Human Interleukin-15* , 2004, Journal of Biological Chemistry.

[38]  R. Strong,et al.  Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. , 2003, Immunity.

[39]  P. Sun,et al.  Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. , 2001, Immunity.

[40]  R. Strong,et al.  Complex structure of the activating immunoreceptor NKG2D and its MHC class I–like ligand MICA , 2001, Nature Immunology.

[41]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[42]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[43]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[44]  P. Stastny,et al.  Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. , 1999, Human immunology.

[45]  L. Lanier.  NK cell receptors. , 1998, Annual review of immunology.

[46]  S. Bahram,et al.  Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  O. Silvennoinen,et al.  Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. , 1994, Science.

[48]  E. Grimm,et al.  Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. , 1993, Cancer research.

[49]  G. Ju,et al.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  F. Bach,et al.  DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells , 1991, The Journal of experimental medicine.